Table 5.

Outcome after renal transplantation in patients with and without recurrent iMN at the end of follow-up

VariablePatients with Recurrent iMN (n = 15)Patients without Recurrence (n = 19)Pa
All Patients with Recurrent iMN (n = 15)Rituximab Treatment (n = 4)
Patients died during follow-up102NS
Patients progressed to ESRD502NS
Serum creatinine (mg/dl)b1.5 ± 0.31.5 ± 0.41.8 ± 1.1NS
Serum BUN (mg/dl)b30.23 ± 10.3038.00 ± 6.3829.44 ± 11.51NS
Estimated GFR (ml/min per 1.73 m2)b51.8 ± 12.245.8 ± 2.447.7 ± 20.0NS
Serum total protein (g/dl)6.6 ± 0.66.4 ± 0.57.0 ± 0.5<0.05
Serum albumin (g/dl)3.9 ± 0.54.1 ± 0.44.3 ± 0.40.01
Serum cholesterol (mg/dl)182 ± 43196 ± 51196 ± 53NS
Proteinuria (g/24 h or g/g creatinine)1.17 ± 1.831.80 ± 2.310.27 ± 0.25NS
Length of follow-up (months; mean ± SE)73.08 ± 18.8780.50 ± 41.3256.67 ± 9.32NS
  • NS = P > 0.05.

  • a Statistical tests were performed on total patients with recurrence compared with patients without recurrence if iMN after renal transplantation.

  • b Includes only the patient who did not develop ESRD.